<bill session="115" type="s" number="2909" updated="2019-04-18T16:43:24Z">
  <state datetime="2018-05-22">REFERRED</state>
  <status>
    <introduced datetime="2018-05-22"/>
  </status>
  <introduced datetime="2018-05-22"/>
  <titles>
    <title type="official" as="introduced">A bill to require the Comptroller General of the United States to study and report on State Medicaid agencies' options related to the distribution of substance use disorder treatment medications under the Medicaid program.</title>
    <title type="short" as="introduced">Assessing Barriers to Opioid Use Disorder Treatment Act</title>
    <title type="short" as="introduced">Assessing Barriers to Opioid Use Disorder Treatment Act</title>
    <title type="display">Assessing Barriers to Opioid Use Disorder Treatment Act</title>
  </titles>
  <sponsor bioguide_id="H001041"/>
  <cosponsors>
    <cosponsor bioguide_id="B001267" joined="2018-05-22"/>
    <cosponsor bioguide_id="M001183" joined="2018-09-12"/>
  </cosponsors>
  <actions>
    <action datetime="2018-05-22">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2018-05-22" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSFI" name="Senate Finance" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="s" session="115" relation="unknown" number="3120"/>
    <bill type="h" session="115" relation="unknown" number="6"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Congressional oversight"/>
    <term name="Drug therapy"/>
    <term name="Drug trafficking and controlled substances"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Government studies and investigations"/>
    <term name="Medicaid"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2018-05-22T04:00:00Z" status="Introduced in Senate">Assessing Barriers to Opioid Use Disorder Treatment Act

This bill requires the Government Accountability Office to report on barriers to the provision of medication used to treat substance use disorders (e.g., buprenorphine) under Medicaid distribution models (e.g., provider purchasing, storage, and administration of medications).</summary>
  <committee-reports/>
</bill>
